Citadel Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

Citadel Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$908K	Sell	131,400 -25,000	-16%	-$193K	﹤0.01%	7883
2025 Q4	$1.38M	Buy	156,400 +136,700	+694%	+$752K	﹤0.01%	6703
2025 Q3	$98.3K	Buy	19,700 +5,900	+43%	+$27.3K	﹤0.01%	11862
2025 Q2	$65.1K	Sell	13,800 -4,400	-24%	-$19.2K	﹤0.01%	11633
2025 Q1	$83.5K	Buy	18,200 +3,800	+26%	+$17.7K	﹤0.01%	11706
2024 Q4	$69K	Sell	14,400 -37,100	-72%	-$178K	﹤0.01%	11990
2024 Q3	$242K	Buy	51,500 +23,200	+82%	+$124K	﹤0.01%	9756
2024 Q2	$160K	Sell	28,300 -7,200	-20%	-$37.2K	﹤0.01%	10244
2024 Q1	$146K	Buy	35,500 +17,300	+95%	+$69.2K	﹤0.01%	10805
2023 Q4	$76.8K	Buy	18,200 +13,700	+304%	+$55.3K	﹤0.01%	11272
2023 Q3	$19.4K	Buy	4,500 +1,700	+61%	+$9.45K	﹤0.01%	12652
2023 Q2	$18.5K	Buy	2,800 +1,100	+65%	+$7.05K	﹤0.01%	12793
2023 Q1	$11.5K	Sell	1,700 -4,400	-72%	-$30.9K	﹤0.01%	13468
2022 Q4	$45.1K	Buy	+6,100	New	+$59.4K	﹤0.01%	12260
2022 Q3	–	Sell	-17,200	Closed	-$187K	–	13684
2022 Q2	$187K	Sell	17,200 -3,300	-16%	-$34.2K	﹤0.01%	10772
2022 Q1	$232K	Sell	20,500 -32,000	-61%	-$421K	﹤0.01%	11177
2021 Q4	$824K	Buy	52,500 +41,800	+391%	+$728K	﹤0.01%	8417
2021 Q3	$183K	Sell	10,700 -5,600	-34%	-$98.1K	﹤0.01%	12107
2021 Q2	$351K	Buy	16,300 +5,500	+51%	+$98.4K	﹤0.01%	10887
2021 Q1	$162K	Buy	+10,800	New	+$175K	﹤0.01%	11955
2020 Q4	–	Sell	-32,900	Closed	-$318K	–	11569
2020 Q3	$318K	Buy	+32,900	New	+$352K	﹤0.01%	8037
2019 Q2	–	Sell	-11,300	Closed	-$208K	–	9916
2019 Q1	$208K	Sell	11,300 -40,500	-78%	-$923K	﹤0.01%	8163
2018 Q4	$1.35M	Buy	51,800 +27,300	+111%	+$642K	﹤0.01%	4799
2018 Q3	$562K	Buy	+24,500	New	+$500K	﹤0.01%	6513
2018 Q2	–	Sell	-12,900	Closed	-$217K	–	9330
2018 Q1	$217K	Buy	+12,900	New	+$216K	﹤0.01%	7225
2017 Q4	–	Sell	-40,500	Closed	-$725K	–	8475
2017 Q3	$725K	Buy	40,500 +29,400	+265%	+$492K	﹤0.01%	4791
2017 Q2	$181K	Buy	+11,100	New	+$160K	﹤0.01%	6625
2017 Q1	–	Sell	-25,200	Closed	-$402K	–	8093
2016 Q4	$402K	Sell	25,200 -10,300	-29%	-$166K	﹤0.01%	5244
2016 Q3	$591K	Buy	35,500 +8,000	+29%	+$108K	﹤0.01%	4598
2016 Q2	$308K	Buy	27,500 +9,200	+50%	+$89.1K	﹤0.01%	5179
2016 Q1	$153K	Sell	18,300 -18,100	-50%	-$149K	﹤0.01%	5818
2015 Q4	$339K	Buy	36,400 +7,600	+26%	+$75.8K	﹤0.01%	5049
2015 Q3	$325K	Sell	28,800 -9,800	-25%	-$120K	﹤0.01%	5449
2015 Q2	$490K	Buy	38,600 +3,700	+11%	+$39.9K	﹤0.01%	5016
2015 Q1	$325K	Buy	34,900 +4,300	+14%	+$48.6K	﹤0.01%	5539
2014 Q4	$438K	Buy	30,600 +200	+0.7%	+$2.37K	﹤0.01%	4910
2014 Q3	$316K	Buy	30,400 +6,100	+25%	+$80K	﹤0.01%	5208
2014 Q2	$393K	Buy	24,300 +2,800	+13%	+$37.3K	﹤0.01%	4711
2014 Q1	$349K	Sell	21,500 -4,000	-16%	-$56.9K	﹤0.01%	4840
2013 Q4	$316K	Sell	25,500 -10,800	-30%	-$108K	﹤0.01%	4550
2013 Q3	$398K	Sell	36,300 -35,000	-49%	-$374K	﹤0.01%	4054
2013 Q2	$576K	Buy	+71,300	New	+$480K	﹤0.01%	3699

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's VNDA Position: Q1 2026 in Review

Citadel Advisors opened a new position in Vanda Pharmaceuticals (VNDA) in Q1 2026: 633,354 shares worth $4.38M. The stake represents ﹤0.01% of the portfolio and ranks #4563 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in VNDA as recently as Q3 2025.

Citadel Advisors first reported a position in VNDA in Q2 2013 and has held it in 49 quarters since. The position peaked at $14.1M in Q3 2017. 170 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

Citadel Advisors held 633,354 shares of Vanda Pharmaceuticals worth $4.38M as of Q1 2026.
Vanda Pharmaceuticals was a new Citadel Advisors position in Q1 2026.
Vanda Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4563 holding.
Citadel Advisors first reported a position in Vanda Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
Citadel Advisors's Vanda Pharmaceuticals position peaked at $14.1M in Q3 2017.
170 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.